talimogene laherparepvec
AXP000001.2 · Oncolytic virus
- Platform
- HSV-1 (JS1 strain, ICP34.5- ICP47-)
- Originator
- BioVex
- Sponsor
- Amgen
Names
| Name | Type | Source |
|---|---|---|
| talimogene laherparepvec | preferred name, INN | curator, ncit |
| Imlygic | brand | ncit |
| JS1 34.5-hGMCSF 47- pA- | code | ncit |
| T-VEC | synonym | ncit |
| OncoVEX GM-CSF | former code | ncit |
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Strain
- JS1
- Replication
- conditionally replicating
- Modifications
- RL1 (ICP34.5) deleted in both copies; US12 (ICP47) deleted, placing US11 under the ICP47 promoter
- Transgenes
- CSF2
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C61314
- Wikidata
- Q7679524
- FDA UNII
- 07730V90L6
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| FDA | US | 2015-10-27 | approved | Imlygic | Local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery | source |
| EMA | EU | 2015-12 | approved | Imlygic | Unresectable melanoma that is regionally or distantly metastatic (stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease | source |
Clinical trials (55)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07102394 | Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 | Recruiting | Phase 1 | 2026-02-01 | 2026-12 | 10 | Cutaneous Neurofibroma; NF1; Neurofibroma; Neurofibromas; Neurofibromatosis; Von Recklinghausen Disease |
| NCT06660810 | Neoadjuvant Intralesional Injection of Talimogene Laherparepvec | Active not recruiting | Phase 2 | 2025-03-03 | 2026-05-26 | 2 | Sarcoma,Soft Tissue; Soft Tissue Sarcoma |
| NCT04065152 | Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma | Unknown | Phase 2 | 2021-01-01 | 2023-02-01 | 20 | Kaposi Sarcoma |
| NCT04599062 | TVEC and Preop Radiation for Sarcoma (8 ml Dose) | Active not recruiting | Phase 1/2 | 2020-09-10 | 2023-02-07 | 8 | Soft Tissue Sarcoma |
| NCT04330430 | Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease | Completed | Phase 2 | 2020-09-08 | 2023-04-09 | 24 | Melanoma Stage III; Melanoma Stage IV |
| NCT04427306 | Neoadjuvant T-VEC in High Risk Early Melanoma | Suspended | Phase 2 | 2020-05-21 | 2022-06-27 | 6 | Melanoma |
| NCT03554044 | T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer | Completed | Phase 1 | 2020-02-05 | 2023-12-31 | 20 | Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Breast Carcinoma |
| NCT04163952 | Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin | Terminated | Phase 1 | 2020-01-31 | 2025-03-28 | 5 | Locally Advanced Skin Squamous Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma; Recurrent Skin Squamous Cell Carcinoma |
| NCT04068181 | Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). | Completed | Phase 2 | 2020-01-22 | 2021-08-19 | 72 | Melanoma |
| NCT02923778 | Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery | Active not recruiting | Phase 2 | 2019-12-31 | 2026-12-29 | 40 | Leiomyosarcoma; Liposarcoma; Sarcoma G2; Sarcoma G3; Soft Tissue Sarcoma; Soft Tissue Sarcoma of the Trunk and Extremities; Stage I Soft Tissue Sarcoma AJCC v7; Stage II Soft Tissue Sarcoma AJCC v7; Undifferentiated Pleomorphic Sarcoma |
| NCT03921073 | Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma | Terminated | Phase 2 | 2019-08-20 | 2021-09-28 | 5 | Angiosarcoma of Skin |
| NCT04185311 | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted | Terminated | Phase 1 | 2019-07-10 | 2023-05-17 | 6 | Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; HER2/Neu Negative; Invasive Ductal Carcinoma, Not Otherwise Specified; Progesterone Receptor Negative; Prognostic Stage 0 Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma |
| NCT03842943 | Neoadjuvant Combination Immunotherapy for Stage III Melanoma | Recruiting | Phase 2 | 2019-07-03 | 2026-06-01 | 28 | Cutaneous Melanoma |
| NCT03972046 | Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma | Withdrawn | Phase 2 | 2019-06-24 | 2020-02-03 | 0 | BRAF Gene Mutation; Melanoma (Skin); Melanoma Stage IIIb-IVM1a; Metastasis Skin; Tumor Skin |
| NCT03663712 | Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies | Completed | Phase 1 | 2019-05-23 | 2022-10-13 | 28 | Peritoneal Surface Malignancy |
| NCT03886311 | Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma | Recruiting | Phase 2 | 2019-05-15 | 2030-12-31 | 200 | Sarcoma |
| NCT03300544 | Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer | Terminated | Phase 1 | 2019-05-14 | 2022-03-22 | 3 | Locally Advanced Rectal Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Rectal Adenocarcinoma; Stage III Rectal Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7 |
| NCT03597009 | A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion | Terminated | Phase 1/2 | 2019-03-06 | 2020-02-07 | 1 | Lung Cancer; Malignant Pleural Effusion; Stage IV Metastatic Cancer |
| NCT03714828 | Study of TVEC in Patients With Cutaneous Squamous Cell Cancer | Completed | Phase 2 | 2018-12-20 | 2023-07-19 | 11 | Cutaneous Tumor; Keratoacanthoma; Lesion Skin; Skin Cancer; Skin Cancer, Squamous Cell; Squamous Cell Carcinoma |
| NCT03802604 | Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer | Completed | Early phase 1 | 2018-12-10 | 2022-04-27 | 28 | Breast Cancer |
| NCT03747744 | Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC) | Unknown | Phase 1 | 2018-09-28 | 2023-10-01 | 18 | Melanoma |
| NCT03555032 | TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion) | Completed | Phase 1/2 | 2018-06-26 | 2021-08-01 | 15 | Melanoma and Sarcoma |
| NCT02965716 | Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | Active not recruiting | Phase 2 | 2018-06-05 | 2023-06-30 | 43 | Advanced Melanoma; Recurrent Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma |
| NCT03430687 | Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma | Withdrawn | Phase 1 | 2018-06-01 | 2019-12-31 | 0 | Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7; Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7; Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7; Stage I Bladder Urothelial Carcinoma AJCC v6 and v7 |
| NCT03458117 | T-VEC in Non-melanoma Skin Cancer | Completed | Phase 1 | 2018-04-19 | 2022-02-04 | 26 | Basal Cell Carcinoma; Cutaneous Lymphoma; Merkel Cell Carcinoma; Non-melanoma Skin Cancer; Squamous Cell Carcinoma |
| NCT03256344 | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | Completed | Phase 1 | 2018-03-19 | 2020-05-26 | 36 | Metastatic Colorectal Cancer; Metastatic Triple Negative Breast Cancer |
| NCT03086642 | Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer | Completed | Phase 1 | 2017-11-16 | 2021-05-13 | 10 | Pancreatic Cancer |
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | Active not recruiting | Phase 2 | 2017-09-27 | 2027-09-01 | 68 | Anaplastic Large Cell Lymphoma, ALK-Negative; Anaplastic Large Cell Lymphoma, ALK-Positive; Apocrine Carcinoma; Carcinoma Arising From Cylindroma; Carcinoma Arising From Spiradenoma; Digital Papillary Adenocarcinoma; Endocrine Mucin-Producing Sweat Gland Carcinoma; Extramammary Paget Disease; Extraocular Sebaceous Carcinoma; Hidradenocarcinoma; Malignant Sweat Gland Neoplasm; Merkel Cell Carcinoma; Microcystic Adnexal Carcinoma; NK-Cell Lymphoma, Unclassifiable; Papillary Adenocarcinoma; Porocarcinoma; Primary Cutaneous Mucinous Carcinoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Merkel Cell Carcinoma; Refractory Mycosis Fungoides; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Skin Squamous Cell Carcinoma; Refractory T-Cell Non-Hodgkin Lymphoma; Sezary Syndrome; Signet Ring Cell Adenocarcinoma; Skin Adenoid Cystic Carcinoma; Skin Adnexal Carcinoma; Skin Basal Cell Carcinoma; Skin Basosquamous Cell Carcinoma; Skin Keratoacanthoma; Skin Squamous Cell Carcinoma; Squamoid Eccrine Ductal Carcinoma; Squamous Cell Carcinoma of Unknown Primary; Sweat Gland Carcinoma; Trichilemmal Carcinoma; Vulvar Squamous Cell Carcinoma |
| NCT02756845 | Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors | Completed | Phase 1 | 2017-08-16 | 2022-01-17 | 15 | Advanced Non CNS Tumors |
| NCT02910557 | Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection | Completed | 2017-08-10 | 2026-01-30 | 187 | Herpetic Infection; Melanoma | |
| NCT03088176 | Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma | Unknown | Phase 1 | 2017-06-25 | 2020-11-30 | 4 | BRAF Gene Mutation; Melanoma |
| NCT02779855 | Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer | Completed | Phase 1/2 | 2017-05-02 | 2020-09-20 | 50 | Breast Cancer; Ductal Carcinoma; Invasive Breast Carcinoma; Invasive Ductal Breast Carcinoma |
| NCT03064763 | Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma | Completed | Phase 1 | 2017-03-07 | 2020-08-03 | 18 | Unresectable Stage IIIB-IV Malignant Melanoma |
| NCT03069378 | A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | Active not recruiting | Phase 2 | 2017-03-03 | 2025-07-22 | 41 | Cutaneous Angiosarcoma; Epithelioid Sarcoma; Sarcoma |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides | Terminated | Phase 1 | 2016-09 | 2020-03-31 | 56 | Breast Carcinoma; Human Papillomavirus-Related Malignant Neoplasm; Melanoma; Merkel-cell Carcinoma; Mycosis Fungoides; Soft Tissue Sarcoma; Solid Tumors; Squamous Cell Carcinoma |
| NCT02658812 | Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery | Terminated | Phase 2 | 2016-08-01 | 2021-12-01 | 11 | Malignant Chest Wall Neoplasm; Recurrent Breast Carcinoma; Recurrent Inflammatory Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Inflammatory Breast Carcinoma |
| NCT02819843 | A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors | Completed | Phase 2 | 2016-06-21 | 2024-02-22 | 19 | Melanoma; Merkel Cell Carcinoma; Other Solid Tumors |
| NCT02626000 | Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) | Completed | Phase 1 | 2016-04-06 | 2017-11-02 | 36 | Carcinoma of the Head and Neck |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 | Completed | Phase 1/2 | 2016-02-05 | 2022-02-14 | 127 | Cutaneous or Subcutaneous Lymph Node; Hepatocellular Carcinoma; Liver Metastases; Liver Tumors |
| NCT02453191 | TVEC and Preop Radiation for Sarcoma (4 ml Dose) | Completed | Phase 1/2 | 2015-07-13 | 2019-01-22 | 30 | Soft Tissue Sarcoma |
| NCT02366195 | Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma | Completed | Phase 2 | 2015-04-07 | 2017-06-26 | 112 | Unresected Stage IIIb to IVM1c Melanoma |
| NCT02288897 | PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma | Terminated | Phase 3 | 2015-04 | 2019-04 | 20 | Cutaneous Melanoma |
| NCT02211131 | Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma | Completed | Phase 2 | 2015-02-03 | 2019-04-30 | 150 | Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma |
| NCT02263508 | Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma | Terminated | Phase 3 | 2014-12-08 | 2021-03-11 | 713 | Melanoma |
| NCT02014441 | Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec | Completed | Phase 2 | 2014-04-07 | 2016-01-25 | 61 | Melanoma |
| NCT01740297 | Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | Completed | Phase 1/2 | 2013-02-07 | 2016-08-23 | 217 | Melanoma |
| NCT01161498 | Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer | Terminated | Phase 3 | 2011-02 | 2011-10 | 5 | Head and Neck Cancer; Squamous Cell Carcinoma |
| NCT01368276 | An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma | Completed | Phase 3 | 2010-10 | 2014-09 | 31 | Melanoma |
| NCT02173171 | Registry Study for Talimogene Laherparepvec | Completed | 2010-04-27 | 2021-09-23 | 185 | Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial | |
| NCT00769704 | Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma | Completed | Phase 3 | 2009-04 | 2013-02 | 437 | Melanoma |
| NCT02574260 | An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016) | Completed | Phase 2 | 2008-08 | 2010-01 | 3 | Melanoma |
| NCT00402025 | Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer | Completed | Phase 1 | 2006-11 | 2008-01 | 17 | Pancreatic Cancer |
| NCT00289016 | A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma | Completed | Phase 2 | 2005-12 | 2008-12 | 50 | Melanoma |
| NCT02297529 | Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma | No longer available | Unresected Stage IIIB to IVM1c Melanoma | ||||
| NCT02147951 | Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma | No longer available | Unresected Stage IIIb to IVM1c Melanoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40910408 | Clinical Pharmacology Characterization of the First-In-Class Oncolytic Viral Therapy T-VEC in Adults and Pediatric Subjects. | Journal of clinical pharmacology | 2026 | name in title: T-VEC |
| PMID 41240988 | A single-arm phase 2 study of talimogene laherparepvec in patients with lower-risk invasive cutaneous squamous cell cancer. | Journal of the American Academy of Dermatology | 2026 | name in title: talimogene laherparepvec |
| PMID 41698899 | Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO). | Nature communications | 2026 | cited by trial NCT03802604 |
| PMID 42130226 | Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer. | Journal of surgical oncology | 2026 | name in abstract: talimogene laherparepvec |
| PMID 42254311 | Acral lentiginous melanoma metastases to the vitreous masquerading as uveitis: A case report. | American journal of ophthalmology case reports | 2026 | name in abstract: talimogene laherparepvec |
| PMID 42257503 | Talimogene Laherparepvec Response in Recurrent Melanoma During Corticosteroid Replacement for Immune Checkpoint Inhibitor-Induced Adrenal Insufficiency: A Case Report. | Journal of immunotherapy (Hagerstown, Md. : 1997) | 2026 | name in title: talimogene laherparepvec |
| PMID 42437516 | Outcomes of Talimogene Laherparepvec in Soft Tissue Sarcoma. | Journal of surgical oncology | 2026 | name in title: talimogene laherparepvec |
| PMID 42618312 | Complete tumour regression of in-transit melanoma following discontinuation of talimogene laherparepvec. | BMJ case reports | 2026 | name in title: talimogene laherparepvec |
| PMID 39522025 | A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases. | Cancer | 2025 | name in abstract: talimogene laherparepvec |
| PMID 39673447 | Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer. | The oncologist | 2025 | cited by trial NCT03086642 |
| PMID 39820126 | Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial). | Nature cancer | 2025 | name in title: talimogene laherparepvec |
| PMID 40132906 | Single-cell analysis of oncolytic virotherapy in adult T-cell leukemia/lymphoma. | Journal for immunotherapy of cancer | 2025 | name in abstract: talimogene laherparepvec |
| PMID 40156118 | Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma. | The oncologist | 2025 | cited by trial NCT02509507 |
| PMID 40417130 | Talimogene laherparepvec induced bullous pemphigoid. | JAAD case reports | 2025 | name in title: talimogene laherparepvec |
| PMID 40945432 | Quantitative habitat concentration analysis of triple negative breast cancer on MRI correlates with pathologic response to combination neoadjuvant immuno/chemotherapy. | Clinical imaging | 2025 | name in abstract: talimogene laherparepvec |
| PMID 41005981 | Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity. | Journal for immunotherapy of cancer | 2025 | name in abstract: talimogene laherparepvec |
| PMID 41170453 | Talimogene Laherparepvec treatment for mucosal melanoma with metastatic lymph node metastasis: case report. | Frontiers in oncology | 2025 | name in title: talimogene laherparepvec |
| PMID 41271741 | Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer. | NPJ breast cancer | 2025 | cited by trial NCT03554044 |
| PMID 41312331 | Recurrent melanoma presenting as a rash: a case report. | Skin health and disease | 2025 | name in abstract: talimogene laherparepvec |
| PMID 38144943 | Locoregional melanoma metastases resistant to PD-1 inhibitor therapy treated with intralesional talimogene laherparepvec. | JAAD case reports | 2024 | name in title: talimogene laherparepvec |
| PMID 38577494 | Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec. | JAAD case reports | 2024 | name in title: talimogene laherparepvec |
| PMID 38664936 | Successful Treatment of Metastatic Primary Cutaneous Adnexal Carcinoma With a PD-1 Inhibitor. | Journal of immunotherapy (Hagerstown, Md. : 1997) | 2024 | cited by trial NCT02978625 |
| PMID 38693123 | Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma. | Nature communications | 2024 | name in title: talimogene laherparepvec |
| PMID 38778387 | Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report. | Journal of medical case reports | 2024 | name in title: talimogene laherparepvec |
| PMID 38870745 | Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115. | European journal of cancer (Oxford, England : 1990) | 2024 | name in title: talimogene laherparepvec |
| PMID 39159678 | A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors. | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | 2024 | name in title: talimogene laherparepvec |
| PMID 39429342 | Intralesional Talimogene Laherparepvec Immunotherapy for Melanoma: A Case Study. | Cureus | 2024 | name in title: talimogene laherparepvec |
| PMID 39562006 | Successful treatment of in-transit metastatic melanoma with combination intralesional T-VEC and topical imiquimod immunotherapy. | Journal for immunotherapy of cancer | 2024 | name in title: T-VEC |
| PMID 35797609 | Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary Practice. | Annals of surgery | 2023 | name in abstract: talimogene laherparepvec |
| PMID 35998300 | Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023 | name in title: talimogene laherparepvec |
| PMID 36564918 | Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma. | CPT: pharmacometrics & systems pharmacology | 2023 | name in title: talimogene laherparepvec |
| PMID 36620496 | Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec. | JAAD case reports | 2023 | name in title: talimogene laherparepvec |
| PMID 36648215 | Neoadjuvant treatment for stage III and IV cutaneous melanoma. | The Cochrane database of systematic reviews | 2023 | cited by trial NCT02211131 |
| PMID 36759673 | Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. | Nature medicine | 2023 | cited by trial NCT02779855 |
| PMID 36863095 | Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases. | ESMO open | 2023 | name in title: talimogene laherparepvec |
| PMID 36959781 | Case report: Therapeutic potential of T-VEC in combination with MEK inhibitors in melanoma patients with NRAS mutation. | Frontiers in oncology | 2023 | name in title: T-VEC |
| PMID 37142291 | Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. | Journal for immunotherapy of cancer | 2023 | name in title: talimogene laherparepvec |
| PMID 37383323 | Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant Patient. | Case reports in dermatology | 2023 | name in title: talimogene laherparepvec |
| PMID 37561473 | Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial. | JAMA oncology | 2023 | name in title: talimogene laherparepvec |
| PMID 37621406 | A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer. | Cancer research communications | 2023 | cited by trial NCT04185311 |
| PMID 37711513 | Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec. | JAAD case reports | 2023 | name in title: talimogene laherparepvec |
| PMID 34519839 | The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides. | Cancer immunology, immunotherapy : CII | 2022 | cited by trial NCT02890368 |
| PMID 35115306 | Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2022 | cited by trial NCT02923778 |
| PMID 35499413 | Complete response of Merkel cell carcinoma with talimogene laherparepvec (TVEC) monotherapy. | Dermatology online journal | 2022 | name in title: talimogene laherparepvec |
| PMID 35656636 | A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma. | Cancer science | 2022 | name in title: talimogene laherparepvec |
| PMID 35666757 | Talimogene laherparepvec resulting in near-complete response in a patient with treatment-refractory Merkel cell carcinoma. | The Australasian journal of dermatology | 2022 | name in title: talimogene laherparepvec |
| PMID 35927710 | Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial. | BMC cancer | 2022 | cited by trial NCT04330430 |
| PMID 36113895 | Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial. | Journal for immunotherapy of cancer | 2022 | cited by trial NCT03747744 |
| PMID 36262357 | Durable melanoma control following disseminated talimogene laherparepvec herpetic infection. | JAAD case reports | 2022 | name in title: talimogene laherparepvec |
| PMID 36312666 | Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma. | Cureus | 2022 | name in title: talimogene laherparepvec |
| PMID 36387105 | Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma. | Frontiers in oncology | 2022 | name in abstract: talimogene laherparepvec |
| PMID 32897942 | Complete and Sustained Remission of Metastatic Cutaneous Squamous Cell Carcinoma in a Liver Transplant Patient Treated With Talimogene Laherparepvec. | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] | 2021 | name in title: talimogene laherparepvec |
| PMID 33219014 | A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2021 | name in title: talimogene laherparepvec |
| PMID 33608376 | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany. | Journal for immunotherapy of cancer | 2021 | name in title: talimogene laherparepvec |
| PMID 33785610 | Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma. | Journal for immunotherapy of cancer | 2021 | name in title: talimogene laherparepvec |
| PMID 34132224 | Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007-2018. | Melanoma research | 2021 | cited by trial NCT03555032 |
| PMID 34189749 | Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma. | Journal of cutaneous pathology | 2021 | name in title: talimogene laherparepvec |
| PMID 34195326 | Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient. | JAAD case reports | 2021 | name in title: talimogene laherparepvec |
| PMID 34235758 | False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC). | Journal of surgical oncology | 2021 | name in title: talimogene laherparepvec |
| PMID 34330766 | Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial. | Journal for immunotherapy of cancer | 2021 | cited by trial NCT02453191 |
| PMID 34437665 | A Case of Recurrent Malignant Melanoma of the Left Foot with In-Transit Metastases. | Rhode Island medical journal (2013) | 2021 | name in abstract: talimogene laherparepvec |
| PMID 34608333 | Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. | Nature medicine | 2021 | name in title: talimogene laherparepvec |
| PMID 34627593 | Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study. | The Lancet. Haematology | 2021 | cited by trial NCT02890368 |
| PMID 34782633 | A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. | Scientific reports | 2021 | name in title: talimogene laherparepvec |
| PMID 31815902 | Talimogene Laherparepvec Use in Kidney Transplant Recipient. | Transplantation | 2020 | name in title: talimogene laherparepvec |
| PMID 31971541 | Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. | JAMA oncology | 2020 | cited by trial NCT03069378 |
| PMID 32050787 | Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database. | Future oncology (London, England) | 2020 | name in title: talimogene laherparepvec |
| PMID 32235165 | Successful Treatment of In-Transit Metastatic Melanoma in a Renal Transplant Patient With Combination T-VEC/Imiquimod Immunotherapy. | Journal of immunotherapy (Hagerstown, Md. : 1997) | 2020 | name in title: T-VEC |
| PMID 32457834 | Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report. | Frontiers in oncology | 2020 | name in title: talimogene laherparepvec |
| PMID 32633563 | SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. | Future oncology (London, England) | 2020 | cited by trial NCT03802604 |
| PMID 32665184 | Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report. | Oral oncology | 2020 | name in title: talimogene laherparepvec |
| PMID 32669371 | Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2020 | cited by trial NCT02626000 |
| PMID 32840157 | Retreatment with talimogene laherparepvec for advanced melanoma. | Immunotherapy | 2020 | name in title: talimogene laherparepvec |
| PMID 33395852 | Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma. | International journal of surgery case reports | 2020 | name in abstract: talimogene laherparepvec |
| PMID 33447351 | Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation. | Oncotarget | 2020 | name in title: T-VEC |
| PMID 30211812 | Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma. | Melanoma research | 2019 | name in title: talimogene laherparepvec |
| PMID 30281140 | Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response. | Acta dermato-venereologica | 2019 | name in title: talimogene laherparepvec |
| PMID 30414194 | The histological spectrum of talimogene laherparepvec (TVEC) injections-Neutrophilic and chronic granulomatous dermatitis. | Journal of cutaneous pathology | 2019 | name in title: talimogene laherparepvec |
| PMID 30477000 | Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma. | JAMA dermatology | 2019 | name in title: talimogene laherparepvec |
| PMID 30690076 | Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience. | Journal of the American College of Surgeons | 2019 | name in title: talimogene laherparepvec |
| PMID 30698924 | Regression of mucosal melanoma following intralesional talimogene laherparepvec (T-VEC) injection in combination with immunotherapy. | Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG | 2019 | name in title: talimogene laherparepvec |
| PMID 30758504 | Extensive Pigment Incontinence Mimicking Persistent Melanoma After Talimogene Laherparepvec Therapy. | JAMA dermatology | 2019 | name in title: talimogene laherparepvec |
| PMID 30776080 | Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report. | The British journal of dermatology | 2019 | name in title: talimogene laherparepvec |
| PMID 30920764 | Rash after a single injection of T-VEC. | Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG | 2019 | name in title: T-VEC |
| PMID 30933044 | Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab. | Journal of immunotherapy (Hagerstown, Md. : 1997) | 2019 | name in title: talimogene laherparepvec |
| PMID 30963012 | Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma. | Case reports in oncological medicine | 2019 | name in title: talimogene laherparepvec |
| PMID 31171039 | Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. | Journal for immunotherapy of cancer | 2019 | cited by trial NCT00769704 |
| PMID 31264725 | Correlates of response and outcomes with talimogene laherperpvec. | Journal of surgical oncology | 2019 | name in abstract: talimogene laherparepvec |
| PMID 31353364 | Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. | British journal of cancer | 2019 | name in title: talimogene laherparepvec |
| PMID 31409575 | Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. | EBioMedicine | 2019 | name in title: talimogene laherparepvec |
| PMID 31414290 | Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size. | Annals of surgical oncology | 2019 | name in title: talimogene laherparepvec |
| PMID 31516997 | Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients. | JAAD case reports | 2019 | name in title: talimogene laherparepvec |
| PMID 31649970 | Complete clinical response to intralesional talimogene laherparepvec injection in a patient with recurrent, regionally advanced Merkel cell carcinoma. | JAAD case reports | 2019 | name in title: talimogene laherparepvec |
| PMID 28940544 | Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases. | Journal of cutaneous pathology | 2018 | name in title: talimogene laherparepvec |
| PMID 28981385 | Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2018 | name in title: talimogene laherparepvec |
| PMID 29112524 | Dermoscopic Guidance of Talimogene Laherparepvec Injection for Metastatic Melanoma. | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] | 2018 | name in title: talimogene laherparepvec |
| PMID 29176501 | Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma. | Melanoma research | 2018 | name in title: talimogene laherparepvec |
| PMID 29561296 | Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors. | Melanoma research | 2018 | cited by trial NCT02147951 |
| PMID 29622046 | Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition. | Journal for immunotherapy of cancer | 2018 | name in title: talimogene laherparepvec |
| PMID 29693076 | Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy. | JAAD case reports | 2018 | name in title: talimogene laherparepvec |
| PMID 29764498 | Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. | Journal for immunotherapy of cancer | 2018 | name in title: talimogene laherparepvec |
| PMID 29896663 | Oncolytic Virotherapy by HSV. | Advances in experimental medicine and biology | 2018 | cited by trial NCT02263508 |
| PMID 30054925 | Panniculitis in a patient with pathologic complete response to talimogene laherparepvec treatment for recurrent, in-transit melanoma. | Journal of cutaneous pathology | 2018 | name in title: talimogene laherparepvec |
| PMID 30450405 | Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma. | JAAD case reports | 2018 | name in title: talimogene laherparepvec |
| PMID 30454071 | Kaposi's varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab. | Journal for immunotherapy of cancer | 2018 | name in title: talimogene laherparepvec |
| PMID 27922859 | FDG-PET/CT for Monitoring Response of Melanoma to the Novel Oncolytic Viral Therapy Talimogene Laherparepvec. | Clinical nuclear medicine | 2017 | name in title: talimogene laherparepvec |
| PMID 28443305 | Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases. | JAAD case reports | 2017 | name in title: talimogene laherparepvec |
| PMID 28445579 | Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-like Infiltrate. | JAMA dermatology | 2017 | name in title: talimogene laherparepvec |
| PMID 28481677 | Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab. | Acta oncologica (Stockholm, Sweden) | 2017 | name in title: talimogene laherparepvec |
| PMID 28642816 | Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma. | Journal for immunotherapy of cancer | 2017 | name in title: T-VEC |
| PMID 28653030 | Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec. | JAAD case reports | 2017 | name in title: talimogene laherparepvec |
| PMID 28738934 | Neoadjuvant Talimogene Laherparepvec for the Treatment of Metastatic Melanoma. | The American surgeon | 2017 | name in title: talimogene laherparepvec |
| PMID 28886381 | Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. | Cell | 2017 | name in abstract: talimogene laherparepvec |
| PMID 28923101 | Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. | Journal for immunotherapy of cancer | 2017 | cited by trial NCT00769704 |
| PMID 27298410 | Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2016 | name in title: talimogene laherparepvec |
| PMID 27342831 | Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. | Annals of surgical oncology | 2016 | name in title: talimogene laherparepvec |
| PMID 27407058 | Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. | Head & neck | 2016 | name in title: talimogene laherparepvec |
| PMID 26014293 | Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2015 | cited by trial NCT00769704 |
| PMID 19915919 | Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. | Annals of surgical oncology | 2010 | name in abstract: OncoVEX GM-CSF |
| PMID 20528232 | OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. | Future oncology (London, England) | 2010 | name in abstract: OncoVEX GM-CSF |
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 32964173 | Breaking β Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapy-Induced Diabetes Mellitus. | Journal of the Endocrine Society | 2020 | name in abstract: T-VEC |
Other papers
Preclinical studies, reviews and other papers that name it, newest 100 shown.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40329730 | Talimogene Laherparepvec (T-VEC): Expanding Horizons in Oncolytic Viral Therapy Across Multiple Cancer Types. | Anti-cancer agents in medicinal chemistry | 2026 | name in title: talimogene laherparepvec |
| PMID 40939516 | Engineered oncolytic herpes simplex virus expressing interleukin 12 suppresses tumorigenicity of hepatocellular carcinoma. | Biochimica et biophysica acta. Molecular basis of disease | 2026 | name in abstract: talimogene laherparepvec |
| PMID 41175341 | Opportunities and challenges in the clinical application of anticancer virotherapy. | Expert review of anticancer therapy | 2026 | name in abstract: talimogene laherparepvec |
| PMID 41542033 | Safety and feasibility of talimogene laherparepvec in peritoneal surface malignancies: Results from the TEMPO trial. | Molecular therapy. Oncology | 2026 | name in title: talimogene laherparepvec |
| PMID 41724916 | Evaluation of Talimogene Laherparepvec for the Treatment of Advanced Nonmelanoma Skin Cancers. | Annals of surgical oncology | 2026 | name in title: talimogene laherparepvec |
| PMID 41754610 | Enhanced Antitumor Activity and Induction of Immunogenic Cell Death in NUT Carcinoma Cells by Combining Oncolytic Viruses with the Dual Inhibitor NEO2734. | Viruses | 2026 | name in abstract: talimogene laherparepvec |
| PMID 41772244 | ASO Visual Abstract: Evaluation of Talimogene Laherparepvec for the Treatment of Advanced Nonmelanoma Skin Cancers. | Annals of surgical oncology | 2026 | name in title: talimogene laherparepvec |
| PMID 41827827 | Oncolytic Viruses in Cancer Immunotherapy: From Molecular Engineering to Clinical Translation. | Cells | 2026 | name in abstract: talimogene laherparepvec |
| PMID 41901211 | Neoantigen-Encoded Oncolytic Viruses as Personalized Cancer Vaccines. | Pharmaceuticals (Basel, Switzerland) | 2026 | name in abstract: talimogene laherparepvec |
| PMID 41990252 | Systemic Therapies for the Treatment of Cutaneous Malignancies in Solid Organ Transplant Recipients. | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] | 2026 | name in abstract: talimogene laherparepvec |
| PMID 42025901 | Efficacy of oncolytic viruses (OVs) in malignant tumor therapy: a review on its therapeutic aspects. | Clinica chimica acta; international journal of clinical chemistry | 2026 | name in abstract: Imlygic |
| PMID 42130334 | Re-evaluating melanoma treatment: a comparative look at herpes simplex virus and coxsackievirus oncolytic therapies in advanced melanoma: a meta-analysis of clinical trials. | Melanoma research | 2026 | name in abstract: talimogene laherparepvec |
| PMID 42204570 | Antitumor activity of Oncolytic Herpes Symplex Virus Type 1 and photodynamic therapy in in vitro preclinical models of glioblastoma. | Journal of translational medicine | 2026 | name in abstract: talimogene laherparepvec |
| PMID 42216079 | Recent advances in oncolytic virotherapy: insights from clinical trials and combination treatment strategies. | Virology journal | 2026 | name in abstract: Imlygic |
| PMID 42327580 | Emerging Oncolytic Viruses: Beyond Adenoviruses and Herpes Simplex Virus. | Journal of Cancer | 2026 | name in abstract: talimogene laherparepvec |
| PMID 42335571 | Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy. | European journal of cancer (Oxford, England : 1990) | 2026 | name in abstract: talimogene laherparepvec |
| PMID 42346244 | The Evolving Role of Intralesional Therapy in In-Transit Melanoma. | Current oncology (Toronto, Ont.) | 2026 | name in abstract: talimogene laherparepvec |
| PMID 42349466 | Updates on intratumoral therapies in melanoma. | Cancer | 2026 | name in abstract: talimogene laherparepvec |
| PMID 42456895 | Oncolytic viruses in cancer therapy: Mechanisms, challenges, and emerging clinical applications. | Annales pharmaceutiques francaises | 2026 | name in abstract: talimogene laherparepvec |
| PMID 42531348 | In silico clinical trials of BiTE expression by oncolytic viruses reveal the impact of patient heterogeneity on dosage protocol. | PLoS computational biology | 2026 | name in abstract: talimogene laherparepvec |
| PMID 42766303 | Vaccines for Cancer: A Translational Science Review. | JAMA | 2026 | name in abstract: talimogene laherparepvec |
| PMID 42809340 | Combined talimogene laherparepvec and binimetinib in NRAS-mutated melanoma induces anti-tumor immunity. | The Journal of clinical investigation | 2026 | name in title: talimogene laherparepvec |
| PMID 42886257 | Oncolytic virotherapy for cancer: biological mechanisms, clinical advances, and future perspectives. | Clinical and experimental medicine | 2026 | name in abstract: talimogene laherparepvec |
| PMID 42910817 | Neoadjuvant Intralesional T-VEC Enabling Digit Preservation in Subungual Acral Melanoma. | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] | 2026 | name in title: T-VEC |
| PMID 42961021 | Neoadjuvant Therapy in Mohs Surgery: A Scoping Review of the Literature. | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] | 2026 | name in abstract: talimogene laherparepvec |
| PMID 42991423 | Intralesional and intratumoral therapies in melanoma: current evidence and future perspectives-a narrative review. | Annals of translational medicine | 2026 | name in abstract: talimogene laherparepvec |
| PMID 39787519 | Effectiveness and safety of talimogene laherparepvec and granulocyte-macrophage colony-stimulating factor for metastatic melanoma: a systematic review and network meta-analysis of randomized controlled trials. | Melanoma research | 2025 | name in title: talimogene laherparepvec |
| PMID 39819188 | Talimogene laherparepvec (T-VEC) as a treatment for melanoma: A systematic review. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | 2025 | name in title: talimogene laherparepvec |
| PMID 40004731 | Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landscape of Immunotherapy. | Journal of clinical medicine | 2025 | name in title: T-VEC |
| PMID 40028913 | Clinical Improvement of Treatment-Resistant Metastatic Basal Cell Carcinoma After Intratumoral Injection of Talimogene Laherparepvec. | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] | 2025 | name in title: talimogene laherparepvec |
| PMID 40171522 | Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2. | Therapeutic advances in medical oncology | 2025 | name in title: talimogene laherparepvec |
| PMID 40213531 | Oncolytic viral therapy for nonmelanoma skin cancer and cutaneous lymphoma - A systematic review. | JAAD international | 2025 | name in abstract: talimogene laherparepvec |
| PMID 40365251 | Investigating the potential of oncolytic viruses in the treatment of melanoma: where do we go from here? | Skin health and disease | 2025 | name in abstract: talimogene laherparepvec |
| PMID 40561062 | Neutralizing monoclonal antibodies improve biodistribution of intravenously administered oncolytic adenovirus in human CD46-transgenic mice. | PloS one | 2025 | name in abstract: talimogene laherparepvec |
| PMID 40596452 | Real world pharmacovigilance study of antineoplastic drug related vitiligo risks. | Scientific reports | 2025 | name in abstract: talimogene laherparepvec |
| PMID 40702727 | Oncolytic HSV and cancer drug interactions: Current clinical status and future directions. | Molecular therapy : the journal of the American Society of Gene Therapy | 2025 | name in abstract: Imlygic |
| PMID 40733704 | Advances in Oncolytic Viral Therapy in Melanoma: A Comprehensive Review. | Vaccines | 2025 | name in abstract: talimogene laherparepvec |
| PMID 40784659 | Analysis of talimogene laherparepvec (T-VEC) safety signals from food and drug administration adverse event reporting system (FAERS). | European journal of pharmacology | 2025 | name in title: talimogene laherparepvec |
| PMID 40827547 | In Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical Translation. | Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2025 | name in abstract: talimogene laherparepvec |
| PMID 40872965 | Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook. | Vaccines | 2025 | name in abstract: talimogene laherparepvec |
| PMID 40881284 | Oncolytic viruses in head and neck cancers: clinical applications and therapeutic potential. | Frontiers in microbiology | 2025 | name in abstract: talimogene laherparepvec |
| PMID 40928075 | Anatomic Location Predicts Response Rates: Real World Outcomes With Over 1100 Cycles of Talimogene Laherparepvec Description: A Retrospective Review of a Prospectively Maintained Database. | Annals of surgery | 2025 | name in title: talimogene laherparepvec |
| PMID 41148835 | The Evolution, Current Landscape, and Future Prospects of Oncolytic Virotherapy in Melanoma: Talimogene Laherparepvec and Beyond. | Cells | 2025 | name in title: talimogene laherparepvec |
| PMID 41448830 | Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma. | Journal for immunotherapy of cancer | 2025 | name in title: talimogene laherparepvec |
| PMID 41451911 | Melanosis Secondary to Drugs: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS). | Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) | 2025 | name in abstract: talimogene laherparepvec |
| PMID 41835051 | Hydrogel Micro/Nanostructures for the Delivery of Oncolytic Viruses: Overcoming Limitations and Improving Efficacy. | Advanced pharmaceutical bulletin | 2025 | name in abstract: talimogene laherparepvec |
| PMID 37578289 | Clinical updates in neoadjuvant immunotherapy for melanoma before surgery. | Expert review of clinical immunology | 2024 | name in abstract: talimogene laherparepvec |
| PMID 37877961 | Oncolytic viral therapy: a review and promising future directions. | Journal of neurosurgery | 2024 | name in abstract: talimogene laherparepvec |
| PMID 38224076 | Clinical and Histological Response to Talimogene Laherparepvec Therapy in Advanced Melanoma: Impact on Overall Survival. | Journal of the American College of Surgeons | 2024 | name in title: talimogene laherparepvec |
| PMID 38444199 | Comparison of the oncolytic activity of a replication-competent and a replication-deficient herpes simplex virus 1. | Immunology | 2024 | name in abstract: talimogene laherparepvec |
| PMID 38527264 | Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma. | Cancer journal (Sudbury, Mass.) | 2024 | name in abstract: talimogene laherparepvec |
| PMID 38562109 | Rescue Rates for Talimogene laherparepvec Use in Loco-Regionally Progressing Cutaneous Melanoma Refractory to PD1 Inhibition. | The American surgeon | 2024 | name in title: talimogene laherparepvec |
| PMID 38576614 | New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy. | Frontiers in immunology | 2024 | name in abstract: talimogene laherparepvec |
| PMID 38599661 | Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. | Journal for immunotherapy of cancer | 2024 | name in abstract: talimogene laherparepvec |
| PMID 38793657 | Multimodal Therapy Approaches for NUT Carcinoma by Dual Combination of Oncolytic Virus Talimogene Laherparepvec with Small Molecule Inhibitors. | Viruses | 2024 | name in title: talimogene laherparepvec |
| PMID 38821716 | Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? | Journal for immunotherapy of cancer | 2024 | name in abstract: talimogene laherparepvec |
| PMID 38893072 | Combined Regional Approach of Talimogene laherparepvec and Radiotherapy in the Treatment of Advanced Melanoma. | Cancers | 2024 | name in title: talimogene laherparepvec |
| PMID 38893078 | Intralesional and Infusional Updates for Metastatic Melanoma. | Cancers | 2024 | name in abstract: talimogene laherparepvec |
| PMID 38921005 | Targeting Cancers with oHSV-Based Oncolytic Viral Immunotherapy. | Current issues in molecular biology | 2024 | name in abstract: Imlygic |
| PMID 39040851 | Translation of oncolytic viruses in sarcoma. | Molecular therapy. Oncology | 2024 | name in abstract: talimogene laherparepvec |
| PMID 39065766 | Where Are We Now with Oncolytic Viruses in Melanoma and Nonmelanoma Skin Malignancies? | Pharmaceuticals (Basel, Switzerland) | 2024 | name in abstract: talimogene laherparepvec |
| PMID 39229331 | Beyond the Scalpel: Advancing Strategic Approaches and Targeted Therapies in Nonexcisable Melanomas. | Journal of skin cancer | 2024 | name in abstract: talimogene laherparepvec |
| PMID 39326128 | Advances in the management of regionally metastatic melanoma. | Surgical oncology | 2024 | name in abstract: talimogene laherparepvec |
| PMID 39456110 | Ultrasound-guided intra-tumoral administration of directly-injected therapies: a review of the technical and logistical considerations. | Cancer imaging : the official publication of the International Cancer Imaging Society | 2024 | name in abstract: talimogene laherparepvec |
| PMID 39602056 | Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review. | Current oncology reports | 2024 | name in title: talimogene laherparepvec |
| PMID 39682138 | Adjuvant Radiation Therapy in Macroscopic Regional Nodal Melanoma. | Cancers | 2024 | name in abstract: talimogene laherparepvec |
| PMID 39687659 | A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma. | Clinical case reports | 2024 | name in title: talimogene laherparepvec |
| PMID 39696696 | Safety of talimogene laherparepvec: a real-world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS). | Journal of pharmaceutical health care and sciences | 2024 | name in title: talimogene laherparepvec |
| PMID 39796696 | Topical and Intralesional Treatments for Skin Metastases and Locoregionally Advanced Melanoma. | Cancers | 2024 | name in abstract: talimogene laherparepvec |
| PMID 36299168 | Oncolytic virus preclinical toxicology studies. | Journal of applied toxicology : JAT | 2023 | name in abstract: talimogene laherparepvec |
Unconfirmed matches (30)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40920359 | A new frontier in oncology: Understanding the landscape of cancer vaccines. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | 2026 | name in abstract: T-VEC |
| PMID 41403403 | Engineering HSV-1 for oncolytic therapy: From molecular entry mechanisms to retargeting strategies. | Genes & diseases | 2026 | name in abstract: T-VEC |
| PMID 41485410 | Overcoming resistance in oncolytic virotherapy: Nano-engineered solutions for systemic delivery and efficacy boost. | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy | 2026 | name in abstract: T-VEC |
| PMID 41675687 | Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery. | Molecular therapy. Oncology | 2026 | name in abstract: T-VEC |
| PMID 41705010 | A Decade of Oncolytic Virotherapy in Pediatric Cancers: A Systematic Review of Safety, Immune Awakening, and Emerging Efficacy. | Cureus | 2026 | name in abstract: T-VEC |
| PMID 42313150 | [Therapy of melanoma : Current standards and future perspectives]. | Pathologie (Heidelberg, Germany) | 2026 | name in abstract: T-VEC |
| PMID 42344931 | Vaccines as treatment for melanoma: an update review. | Frontiers in immunology | 2026 | name in abstract: T-VEC |
| PMID 42504409 | Oncolytic Virotherapy, Long Stalled, Nears Second Approval. | Cancer discovery | 2026 | name in abstract: T-VEC |
| PMID 42648642 | Engineering HSV-1 for gene therapy, oncolytic immunotherapy, and neuroscience. | Virologica Sinica | 2026 | name in abstract: T-VEC |
| PMID 43005928 | The synthetic biology frontier: engineered oncolytic viruses and viral vectors for next-generation cancer therapy and gene delivery. | RSC advances | 2026 | name in abstract: T-VEC |
| PMID 39422848 | Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis. | Annals of surgical oncology | 2025 | name in abstract: T-VEC |
| PMID 40069043 | HSV-1 as a gene delivery platform for cancer gene therapy. | Trends in pharmacological sciences | 2025 | name in abstract: T-VEC |
| PMID 40123637 | Cancer Vaccines: A Novel Revolutionized Approach to Cancer Therapy. | Indian journal of clinical biochemistry : IJCB | 2025 | name in abstract: T-VEC |
| PMID 40223683 | In Situ Cancer Vaccines: Redefining Immune Activation in the Tumor Microenvironment. | ACS biomaterials science & engineering | 2025 | name in abstract: T-VEC |
| PMID 40285023 | Advances in the Drug Development and Quality Evaluation Principles of Oncolytic Herpes Simplex Virus. | Viruses | 2025 | name in abstract: T-VEC |
| PMID 40305928 | Advances and challenges in cancer immunotherapy: Strategies for personalized treatment. | Seminars in oncology | 2025 | name in abstract: T-VEC |
| PMID 40685482 | Oncolytic virotherapy and tumor microenvironment modulation. | Clinical and experimental medicine | 2025 | name in abstract: T-VEC |
| PMID 40977706 | Opportunities, challenges, and future perspectives of oncolytic virus therapy for malignant melanoma. | Frontiers in immunology | 2025 | name in abstract: T-VEC |
| PMID 40991899 | A New Era in Oncology: Clinical Insights Into the Application of Oncolytic Viruses. | Cancer control : journal of the Moffitt Cancer Center | 2025 | name in abstract: T-VEC |
| PMID 41296382 | Recombinant Oncolytic Viruses: Hexagonal Warriors in the Field of Solid Tumor Immunotherapy. | Current issues in molecular biology | 2025 | name in abstract: T-VEC |
| PMID 41463198 | Oncolytic Viruses in Glioblastoma: Clinical Progress, Mechanistic Insights, and Future Therapeutic Directions. | Cancers | 2025 | name in abstract: T-VEC |
| PMID 41662640 | Review Article: Intratumoral Immunotherapy: Old Discoveries and Recent Developments in Sarcomas. | Critical reviews in oncogenesis | 2025 | name in abstract: T-VEC |
| PMID 38171406 | Advances and prospects of mRNA vaccines in cancer immunotherapy. | Biochimica et biophysica acta. Reviews on cancer | 2024 | name in abstract: T-VEC |
| PMID 38435173 | HIV-Encoded Gene Therapy as Anti-cancer Therapeutics: A Narrative Review. | Cureus | 2024 | name in abstract: T-VEC |
| PMID 38750345 | Access to melanoma drugs in Spain: a cross-sectional survey. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2024 | name in abstract: T-VEC |
| PMID 38941955 | Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures. | EBioMedicine | 2024 | name in abstract: T-VEC |
| PMID 39044819 | Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors. | Frontiers in immunology | 2024 | name in abstract: T-VEC |
| PMID 39239066 | Synergistic effects of herpes oncolytic virus and cyclophosphamide for recurrent malignant glioma: a narrative review. | Annals of medicine and surgery (2012) | 2024 | name in abstract: T-VEC |
| PMID 39293238 | Breaking Barriers: Animal viruses as oncolytic and immunotherapeutic agents for human cancers. | Virology | 2024 | name in abstract: T-VEC |
| PMID 36044068 | Local anesthetics and immunotherapy: a novel combination to fight cancer. | Seminars in immunopathology | 2023 | name in abstract: T-VEC |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| P01CA163205 | Project 3: Circumventing extracellular Adenosine barrier to oncolytic virotherapy | BRIGHAM AND WOMEN'S HOSPITAL | KAUR, BALVEEN | 2023–2026 | name in abstract: Imlygic |
| R01CA269002 | Actively engaging NK cells during virotherapy to induce neoantigen-specific antitumor immunity | UNIVERSITY OF HOUSTON | ZHANG, SHAUN XIAOLIU | 2022–2026 | name in abstract: talimogene laherparepvec |
| R21CA303392 | Boosting Oncolytic HSV Immunotherapy by Enabling Necroptosis | LOUISIANA STATE UNIV HSC SHREVEPORT | GUO, HONGYAN | 2025–2025 | name in abstract: talimogene laherparepvec |
| R43CA298595 | Preclinical development of VAX024 - a novel targeted combination STING agonist/oncolytic agent | VAXIION THERAPEUTICS, INC. | GIACALONE, MATTHEW | 2025–2025 | name in abstract: Imlygic |
| R21NS123685 | IGF1R-targeted oncolytic herpes simplex viral therapy for Glioblastoma | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON | YOO, JI YOUNG | 2022–2023 | name in abstract: talimogene laherparepvec |
| R43HG012745 | Development of GenomeBuild as a Universal Method to Synthesize Genomes | PROTEOVISTA, LLC | WARREN, CHRISTOPHER L | 2023–2023 | name in abstract: talimogene laherparepvec |
| R33NS112410 | Optimizing oncolytic virus therapy for glioblastoma | AUGUSTA UNIVERSITY | KAUR, BALVEEN | 2022–2022 | name in abstract: Imlygic |
| F31CA235898 | Developing polycistronic replication-defective herpes simplex virus vectors as immunotherapeutic tools for treating melanoma | HARVARD MEDICAL SCHOOL | WALSH, MICHAEL | 2020–2020 | name in abstract: talimogene laherparepvec |
| R01FD006108 | Ph1 Study of T-Vec given endoscopically for advanced pancreatic cancer IN 17248 (11/21/2016) | COLUMBIA UNIVERSITY HEALTH SCIENCES | SAENGER, YVONNE MARGARET | 2018–2020 | name in title: T-VEC |
| R61NS112410 | Optimizing oncolytic virus therapy for glioblastoma | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON | KAUR, BALVEEN | 2019–2020 | name in abstract: Imlygic |
| 75N91019D00 | Biopsy Support with Patients with Advanced Melanoma | LEIDOS BIOMEDICAL RESEARCH, INC. | FREEDMAND, LEONARD | 2019–2019 | name in abstract: talimogene laherparepvec |
| F32NS108528 | Oncolytic virotherapy targeting RAGE signaling in glioblastoma | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON | SWANNER, JESSICA | 2018–2018 | name in abstract: talimogene laherparepvec |
Unconfirmed matches (4)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R01CA224605 | Dual-pronged nano-drug delivery using plant virus-like particles. | UNIVERSITY OF CALIFORNIA, SAN DIEGO | STEINMETZ, NICOLE FRANZISKA | 2017–2021 | name in abstract: T-VEC |
| U01CA218292 | Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology. | UNIVERSITY OF CALIFORNIA, SAN DIEGO | STEINMETZ, NICOLE FRANZISKA | 2017–2021 | name in abstract: T-VEC |
| R44CA233024 | Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors | VYRIAD, INC. | RUSSELL, LUKE O. | 2018–2020 | name in abstract: T-VEC |
| R01CA187923 | Novel Strategies to Potentiate a Ras-targeted Oncolytic Herpes Simplex Virus | UNIVERSITY OF HOUSTON | ZHANG, SHAUN XIAOLIU | 2015–2019 | name in abstract: T-VEC |
Notes
FDA approved 2015 as Imlygic; BioVex acquired by Amgen 2011. OncoVEX GM-CSF was the BioVex-era development name. Transgenes moved from targets to virus.tsv (spec 0.2).
How to cite
talimogene laherparepvec (AXP000001.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000001.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.